Targeting dual signalling pathways in concert with immune checkpoints for the treatment of pancreatic cancer
- 18 May 2020
- Vol. 70 (1), 127-138
- https://doi.org/10.1136/gutjnl-2020-321000
Abstract
Objective This study exploits the intersection between molecular-targeted therapies and immune-checkpoint inhibition to define new means to treat pancreatic cancer. Design Patient-derived cell lines and xenograft models were used to define the response to CDK4/6 and MEK inhibition in the tumour compartment. Impacts relative to immunotherapy were performed using subcutaneous and orthotopic syngeneic models. Single-cell RNA sequencing and multispectral imaging were employed to delineate effects on the immunological milieu in the tumour microenvironment. Results We found that combination treatment with MEK and CDK4/6 inhibitors was effective across a broad range of PDX models in delaying tumour progression. These effects were associated with stable cell-cycle arrest, as well as the induction of multiple genes associated with interferon response and antigen presentation in an RB-dependent fashion. Using single-cell sequencing and complementary approaches, we found that the combination of CDK4/6 and MEK inhibition had a significant impact on increasing T-cell infiltration and altering myeloid populations, while potently cooperating with immune checkpoint inhibitors. Conclusions Together, these data indicate that there are canonical and non-canonical features of CDK4/6 and MEK inhibition that impact on the tumour and immune microenvironment. This combination-targeted treatment can promote robust tumour control in combination with immune checkpoint inhibitor therapy.Keywords
Funding Information
- National Cancer Institute (CA211878)
This publication has 56 references indexed in Scilit:
- A randomised, double-blind, placebo-controlled trial of trametinib, an oral MEK inhibitor, in combination with gemcitabine for patients with untreated metastatic adenocarcinoma of the pancreasEuropean Journal of Cancer, 2014
- CDK4/6 and IGF1 Receptor Inhibitors Synergize to Suppress the Growth of p16INK4A-Deficient Pancreatic CancersCancer Research, 2014
- Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic CancerCell, 2014
- Influence of the Implantation Site on the Sensitivity of Patient Pancreatic Tumor Xenografts to Apo2L/TRAIL TherapyPancreas, 2014
- Activated Pancreatic Stellate Cells Sequester CD8(+) T Cells to Reduce Their Infiltration of the Juxtatumoral Compartment of Pancreatic Ductal AdenocarcinomaGastroenterology, 2013
- A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapyInvestigational New Drugs, 2011
- Mammalian Cells Cycle without the D-Type Cyclin-Dependent Kinases Cdk4 and Cdk6Cell, 2004
- A Network of Immediate Early Gene Products Propagates Subtle Differences in Mitogen-Activated Protein Kinase Signal Amplitude and DurationMolecular and Cellular Biology, 2004
- Inhibition of Ras-Induced Proliferation and Cellular Transformation by p16 INK4Science, 1995
- A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4Nature, 1993